Changing epidemiology in patients with heart failure

John Gierula, PhD; Mark T. Kearney MD, FRCP
Leeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Leeds, LS2 9JT, UK

Correspondence: Mark Kearney, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS2 9JT, United Kingdom
E-mail: m.t.kearney@leeds.ac.uk

Abstract: Heart failure (HF) and type 2 diabetes mellitus (DM) are current global epidemics with increasing prevalence that show no signs of slowing down. Of particular concern is the burden that both of these disorders place on individuals and society as a whole. Individually, both are expensive in resources, have high mortality rates, and cause significant reductions in quality of life. However, 30% to 45% of patients with HF have DM, and DM is an independent risk factor for the development of progressive HF and cardiovascular death, complicating management for physicians and further raising pressures on health and social care systems. Breakthroughs in the medical management of DM and HF have reduced mortality rates, meaning that the current epidemic is largely fueled by increased prevalence of the two disorders. Of particular concern is the rise of DM in developing countries, as these areas of the world become more prosperous, with the trappings of Western civilization rapidly infiltrating their cultures. Subsequent declines in physical activity and increased consumption of refined foods, drastically removed from indigenous eating habits, are resulting in DM sweeping the globe.

Keywords: diabetes mellitus; epidemiology; heart failure; heart failure with reduced ejection fraction; heart failure with preserved ejection fraction

Introduction

The prevalence of type 2 diabetes mellitus (DM) and heart failure (HF) have reached epidemic proportions, generating major challenges to health and social care systems globally. Both conditions are associated with reduced quality of life, frequent hospitalization and are leading causes of mortality. An epidemic can reflect increased incidence, increased survival leading to increased prevalence, or both factors combined. In the case of HF and DM both increased incidence and survival have contributed to the rise in both of these disorders; it is estimated that 38 million people in the world are affected by HF, and figures from the International Diabetes Foundation (IDF) indicate that in 2017 425 million adults were living with DM - a figure projected to rise to 629 million by 2045. It is becoming increasingly understood that HF is not an independent pathology, but rather a heterogeneous group of conditions presenting with the classic symptoms of the HF syndrome: fatigue, breathlessness, and edema. Historically HF has been viewed as a failure of left ventricular (LV) contractile function, with reduced left ventricular ejection fraction (LVEF) being used to define systolic dysfunction, assess prognosis, and select patients for therapeutic interventions. However, it is now well established that HF can occur in the presence of normal or near-normal LVEF: this HF with preserved ejection fraction EF (HFP EF) now accounts for a substantial proportion of clinical cases of HF. 

Heart Metab. 2019;80:4-7
HF is frequently accompanied by a number of co-morbid conditions, complicating management for physicians and contributing to worsening morbidity and mortality. These comorbidities include, but are not limited to, renal disease, obesity, anemia, and type 2 diabetes mellitus (DM). DM is an independent risk factor for the development of progressive HF and cardiovascular death, and is present in 30% to 45% of people with existing HF, which, when combined with alarming projections for future prevalence, implicates DM as perhaps the most important comorbidity of all in HF.

Type 2 diabetes mellitus

Traditionally viewed as a disease of affluent Western society, DM has now spread to all four corners of the globe, and there are now more people living with type 2 diabetes in developing societies than in industrialized nations. It is estimated that the number of adults with DM in the world increased from 108 million in 1980 to 425 million in 2017, with growth and aging of the world population, the global obesity epidemic, and the success of cardiovascular risk management and treatment being key factors in this meteoric rise. The spread of the DM epidemic to the developing world adds a further challenge to health care systems already under strain from contending with communicable diseases. Inadequate prevention strategies, delayed diagnosis, and substandard aftercare of people with diabetes raises the risk of developing future complications such as ischemic heart disease (IHD), further increasing the burden on societies lacking sufficiently funded health care systems.

Heart failure with reduced ejection fraction

Arising as a consequence of a number of conditions impacting on LV function, including coronary artery disease, valvular heart disease, and hypertension, heart failure with reduced ejection fraction (HFrEF) remains a major cause of death and disability worldwide. The second half of the 20th century saw little change in the incidence of HFrEF among men, a drop of one third in incidence among women and a one third decline in mortality following the onset of HF in both sexes. Despite positive trends in mortality, HFrEF remained deadly: 50% of patients given a diagnosis of HFrEF in the 1990s, when annual incidence in North America was around half a million cases, were dead at 5 years.

Continued advancements in our understanding of the underlying pathophysiology of HFrEF led to developments in pharmacological treatment, and device therapy which, when combined with improved post-myocardial infarction survival rates resulted in the first decade of the 21st century witnessing a simultaneous reduction in cardiovascular mortality and HFrEF incidence. However, conflicting data from a recent population-based study in the United Kingdom raises cause for concern. From 2002 to 2014, the incidence of HF decreased by 7% from 358 to 332 per 100 000 person-years). But, the number of individuals with a new diagnosis of HF increased by 12%, from an estimated figures of 170 727 in 2002 to 190 798 in 2014, largely attributed to ageing and increases in population. This was accompanied by a 23% increase in the absolute number of patients with HF in the UK, a rise from 750 127 in 2002 to 920 616 equates to a 23% increase in prevalence over this period.

Heart failure with preserved ejection fraction

The ongoing change in the HF landscape is also influenced by a higher proportion of diagnoses being attributed to HFrEF. Understanding the epidemiology of HFrEF has been challenging due to the heterogeneity of underlying etiology and pathophysiology, making diagnosis difficult. Despite this there is general consensus that prevalence of HFrEF is increasing. A review of 31 studies conducted from 1970 to 1995 HF found between 13% and 74% (median 40%) of patients investigated for HF had HFrEF, and following this 12 studies published from 1998 to 2003, found the prevalence of HFrEF to be between from 40% to 71% (mean 54%). As of yet no therapeutic intervention has proven to be effective in HFrEF consequently, this increased prevalence is unlikely to change in the near future. Alongside an emphasis on multiple phenotypes of HFrEF, there is a growing consensus about HFrEF being more of a systemic disease with adverse consequences in multiple organs than one involving exclusively the heart. A number of studies have suggested that DM is an important risk factor for all-cause mortality in patients with HFrEF identifying the presence of DM as an important phenotype of HFrEF, which may have implications for therapeutic strategies.
Conclusion

Both DM and HF represent a significant problem for society; individually both are expensive of resources and are leading causes of morbidity and mortality, but as comorbidities they result in significantly worse outcomes for an increasing number of people who suffer from both conditions. Advancements in medical therapy have shifted the landscape of both DM and HF: favorable impacts on mortality have the challenging effect of increased health care utilization, which is increasingly becoming a problem in countries with less developed and under resourced health care systems. The problems presented by DM and HF are too great for the scientific community to handle on their own; whilst emerging nations cannot be deprived of their chance to develop financially and socially, there is a desperate need for higher-level intervention, to ensure that the necessary education on lifestyle management is delivered to stem the tide of this deadly duo.

Disclosure/Acknowledgments: Mark Kearney is British Heart Foundation Professor of Cardiovascular and Diabetes Research, John Gierula is National Institute of Health Research Clinical Lecturer.

REFERENCES


